Dronedarone (Multaqâ–¼) is an antiarrhythmic agent indicated in adult, clinically stable patients with history of, or current, non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. Dronedarone is available as a 400 mg film-coated tablet and the recommended dose is 400 mg twice daily.

Dronederone was only approved by NICE as a second line drug in August 2010. Use of dronedarone may be associated with:

  • an elevated risk of worsening, or new-onset, heart failure
  • liver toxicity

Patients should be asked to be vigilant for the symptoms of heart failure or liver toxicity during treatment, and should undergo regular liver-function testing.

More advise for healthcare professional can be found here.

Leave a comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.